Literature DB >> 21575418

[Expression of Piwil2 and its relationship with tumor invasion and metastasis in papillary thyroid carcinoma].

De-tao Yin1, Hong-qiang Li, Yong-fei Wang, Sheng-li Cao, Yu-bing Zhou, Li-yun Zheng, Jin-hua Jiang, Qing-duan Wang.   

Abstract

OBJECTIVE: To study the expressions of Piwil2 protein and mRNA in papillary thyroid carcinoma (PTC) and the relationship between Piwil2 and the invasion and metastasis of PTC.
METHODS: Immunohistochemistry and in situ hybridization were used to detect the expression of Piwil2 protein and mRNA in 60 cases of PTC with the matched adjacent non-cancerous epithelium (NCE).
RESULTS: The positive rates of Piwil2 protein expression in PTC and NCE were 88.3% (53/60) and 10.0% (6/60) respectively, with significant difference (χ² = 73.654, P < 0.01). The positive rates of Piwil2 mRNA expression in PTC and NCE were 85.0% (51/60) and 6.7% (4/60) respectively, also with significant difference (χ(2) = 74.148, P < 0.01). Up-regulated expressions of Piwil2 protein and mRNA were related to the invasion and metastasis of PTC (P < 0.05).
CONCLUSIONS: Piwil2 may play a role in the invasion and metastasis of PTC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21575418

Source DB:  PubMed          Journal:  Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi        ISSN: 1673-0860


  2 in total

1.  Piwil2 modulates the invasion and metastasis of prostate cancer by regulating the expression of matrix metalloproteinase-9 and epithelial-mesenchymal transitions.

Authors:  Yanfeng Yang; Xuepei Zhang; Dongkui Song; Jinxing Wei
Journal:  Oncol Lett       Date:  2015-06-19       Impact factor: 2.967

2.  Expression profiles of PIWIL2 short isoforms differ in testicular germ cell tumors of various differentiation subtypes.

Authors:  Ildar V Gainetdinov; Yulia V Skvortsova; Elena A Stukacheva; Oksana S Bychenko; Sofia A Kondratieva; Marina V Zinovieva; Tatyana L Azhikina
Journal:  PLoS One       Date:  2014-11-10       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.